The Diagnosis & Management of Diabetes in Pregnancy

Objectives

Provide an evidence-based national clinical framework for the diagnosis, management and referral of diabetes mellitus in pregnancy in Qatar, improving maternal, fetal and neonatal outcomes while supporting individualised decisions made jointly with women, families or carers.[1][2]The scope spans pre-conception care, diabetes screening in pregnancy, gestational diabetes mellitus, pre-existing type 1 and type 2 diabetes, complications, intrapartum care, postnatal care, future pregnancy planning and patient-centred communication.[3][4][5][6]

• Reduce maternal, fetal and neonatal complications through planned pregnancy, glycaemic optimisation, early identification of diabetes, appropriate treatment and structured surveillance.[7][8][9]
• Integrate pre-conception care into routine diabetes services and coordinate specialist diabetes and maternity services for women planning pregnancy.[10][7]
• Promote informed pregnancy planning, including contraception until glycaemic control is optimised, medication review, complication assessment and counselling on residual risks despite risk reduction.[11][12]
• Identify undiagnosed type 2 diabetes and gestational diabetes through risk-based antenatal screening, with testing differentiated for average-risk and high-risk women.[13][8]
• Support gestational diabetes management through education, dietary planning, safe physical activity, appropriate weight gain and pharmacotherapy where lifestyle measures do not achieve glycaemic targets.[14][15][16]
• Maintain pregnancy-specific glucose targets while minimising problematic hypoglycaemia, including fasting glucose below 5.3 mmol/L, one-hour post-meal glucose below 7.8 mmol/L and two-hour post-meal glucose below 6.7 mmol/L where safely achievable.[17][18]
• Provide safe labour, birth and postnatal care, including neonatal hypoglycaemia prevention, breastfeeding support, postpartum diabetes testing and long-term prevention of type 2 diabetes after gestational diabetes.[19][5][20]
• Respect patient preferences, confidentiality, dignity, informed consent, shared decision making and accessible communication throughout care.[6]

Implementation

Deliver care principally through primary care, maternity and specialist services using a diabetes-in-pregnancy clinical pathway, multidisciplinary teams, risk-based referral and evidence-informed, individualised treatment.[1][2][21]The Ministry of Public Health of Qatar developed and issued the guideline through a process aligned with international best practice and adapted to the national context, with oversight by the National Clinical Guidelines and Pathways Committee.[4][2]

• Base development on systematic literature searches, critical appraisal and a Guideline Development Group comprising healthcare professionals, subject experts, evidence-based medicine specialists and patient representatives; obtain independent committee review and maintain editorial independence from Ministry sponsorship.[4][22]
• Coordinate adult diabetes, maternity, obstetric, endocrinology, dietetic, health education and neonatal services, referring women to specialist pre-conception or antenatal care when primary care cannot safely manage their needs.[10][7][21][23]
• Provide pre-conception counselling, dietary advice, weight and activity support, folic acid, glucose monitoring, medication review and screening for renal and retinal complications, with specialist referrals for identified risk.[12][13]
• Apply screening pathways using fasting blood glucose, glycated haemoglobin and 75 gram oral glucose tolerance testing according to pregnancy risk, gestational age, test tolerance and bariatric-surgery history.[8][21]
• Provide women with reliable, recently calibrated home glucometers; tailor self-monitoring from four daily measurements for diet, metformin or single basal-insulin treatment to six or seven measurements for multiple daily insulin injections.[17][18]
• Start gestational diabetes treatment with diet and physical activity, offer metformin when lifestyle measures are insufficient where appropriate, and initiate or add insulin when metformin is contraindicated, unacceptable, not tolerated or inadequate.[16]
• Use multiple daily insulin injections for most women with pre-existing diabetes, support self-adjustment of insulin doses, maintain contact with diabetes educators, and consider continuous glucose monitoring or pump therapy for selected insulin-treated women.[18][24]
• Undertake antenatal monitoring of blood pressure, urine protein, body weight and self-monitored glucose, alongside fetal surveillance through early pregnancy assessment, anomaly scanning and serial growth and amniotic-fluid assessment adapted to maternal and fetal circumstances.[21][17][9]
• Plan timing and mode of delivery according to glycaemic control, maternal complications and fetal status; during labour, monitor glucose hourly and consider variable-rate insulin infusion when clinically indicated.[25][19]
• Provide postnatal neonatal feeding and glucose monitoring, adjust maternal insulin treatment, encourage breastfeeding, and arrange a 75 gram oral glucose tolerance test four to twelve weeks after gestational diabetes followed by annual glycaemic monitoring.[5][20]
• Monitor organisational performance using specified indicators, including gestational diabetes testing at 24 to 28 weeks, pre-conception folic acid prescribing for women with diagnosed diabetes, and glycated haemoglobin measurement at booking for women with pre-existing diabetes.[26]
• Review and update the guideline regularly in response to stakeholder feedback; the supplied material does not specify a wider reporting system, audit cycle, budget, financing arrangement or quantified implementation resources.[4][26][27]

Monitoring & Evaluation

Monitoring combines clinical targets, scheduled maternal and fetal assessment, postnatal follow-up, performance measures and governance review. The guideline provides limited detail on programme-wide reporting, audit, surveillance and accountability arrangements beyond these mechanisms.[1][8][21][18][24][26]

• Measure glycaemic control against pregnancy-specific targets, including fasting blood glucose below 5.3 mmol/L, one-hour post-meal glucose below 7.8 mmol/L and two-hour post-meal glucose below 6.7 mmol/L, where this is achievable without problematic hypoglycaemia.[28][17][18]Maintain capillary glucose above 4 mmol/L for insulin-treated patients.[17][18]
• Tailor home blood-glucose monitoring to treatment, generally using four daily measurements for diet-only, metformin or single basal-insulin regimens and up to six or seven daily measurements for multiple daily injections.[28][29][12][17][18]Add nocturnal testing where night-time hypoglycaemia is suspected.[12]
• Use glycated haemoglobin measurement before conception and at booking or initial review.[10][7][18][26]Guidance on repeat testing differs by clinical pathway: one section does not recommend routine repeat measurement after diagnosis, while another advises measurement at least once per trimester, with frequency determined by the treating physician.[28][17][18]
• Review blood pressure, urine protein, body weight and self-monitored glucose at antenatal visits, normally every one to three weeks after gestational diabetes diagnosis according to individual need.[21]Monitor renal risk through serum creatinine, urinary albumin-to-creatinine ratio and protein excretion, and assess retinal status before conception or during pregnancy according to diabetes status and retinopathy risk.[13][24][30]
• Conduct fetal surveillance through early viability, nuchal translucency and anomaly scans, followed by serial growth and amniotic-fluid assessment.[28][29][17][9]Assess fetal growth approximately every four weeks from 24 weeks, with additional ultrasound, biophysical profile testing or Doppler studies guided by glycaemic control, fetal growth, maternal health and co-morbidities.[29][17][9]Encourage maternal monitoring of fetal movements from 24 weeks and arrange hospital assessment and cardiotocography where movements change.[28][16][9]
• Monitor blood glucose hourly during labour, with more frequent checks during caesarean section under general anaesthesia.[25][19][31]Monitor fetal status by cardiotocography when maternal blood glucose exceeds 12 mmol/L until normoglycaemia is restored.[31]
• Undertake neonatal glucose testing within one to four hours after birth where neonatal hypoglycaemia is a concern, support early and frequent feeding, and maintain pre-feed capillary plasma glucose at a minimum of 2.0 mmol/litre.[5][20]Perform a 75-gram oral glucose tolerance test four to twelve weeks postpartum for women with gestational diabetes, then provide annual glycated haemoglobin or fasting-glucose monitoring.[5]
• Track three specified organisational performance indicators: DP001, the proportion of eligible women receiving a 75-gram oral glucose tolerance test at 24 to 28 weeks; DP002, the proportion of pregnant women with diagnosed diabetes prescribed 5 mg folic acid daily from at least three months before conception; and DP003, the proportion of women with pre-existing diabetes who have glycated haemoglobin measured at booking.[26]
• Review and update the guideline regularly in response to stakeholder comments and feedback.[4]Apply evidence and recommendation grading, require review and approval by the Guideline Development Group and National Clinical Guidelines and Pathways Committee, and retain reviewed conflict-of-interest declarations at the Ministry of Public Health of Qatar.[4][22][2]

Although the guideline identifies clinical thresholds, referral triggers and three performance indicators, the supplied material does not specify reporting schedules, data systems, audit cycles, a surveillance registry, consequences for underperformance or a comprehensive accountability framework.[8][21][18][24][19][31][26]

Costing & Financing

No implementation budget, unit costs, dedicated allocation, funding gap, resource-mobilisation plan or economic evaluation is specified for diabetes-in-pregnancy services.[32][3][1][18][24][6][26]

• Require clinical inputs including calibrated home glucometers, glucose testing supplies, insulin and glucose infusions, medicines, dietetic support, specialist diabetes and maternity care, fetal surveillance, cardiotocography, neonatal monitoring and, where needed, high-dependency or neonatal-unit care.[29][21][30][23][19][31][5][20]No associated monetary valuation or financing source is provided.[30][9][23]
• Identify one contributor as funded through Qatar National Research Fund Programme Grant NPRP 10-0129-170274, but do not provide the grant value, period, or a link between this support and service-delivery financing.[27]

The supplied material therefore supports identification of resource requirements, but not costing, affordability analysis, budget impact, financial responsibility or economic assumptions.[17][16][19][31][27]